BWS Financial analyst Hamed Khorsand said he believes Anika Therapeutics' (ANIK) agreement to purchase Arthosurface and Parcus Medical "might create greater obstacles than opening new opportunities" as those companies' focus on sports medicine could set the company up for competition with partner DePuy Synthes Mitek Sports Medicine, a division of a subsidiary of Johnson & Johnson (JNJ). The competition could be looked upon poorly by DePuy, which currently represents over 70% of Anika's revenue, contends Khorsand, who believes the risks related to the partnership outweigh any of the revenue growth benefits from the deals. He keeps a Sell rating and $29 price target on Anika shares.

BTIG notes that seven Medicare Administrative Contractors, or MACs - CGS, WPS, NGS, Palmetto, Novitas, First Coast, and Noridian - this morning published new proposed local coverage determinations, or LCDs, regarding the coverage of skin substitutes grafts and cellular and tissue based products for the treatment of diabetic foot ulcers, or DFUs, and venous leg ulcers, or VLUs. This marks "the second attempt in the past 12 months where MACs have proposed an LCD that would drastically shake up the advanced wound care market," says the analyst, who highlights that the proposed LCD includes non-coverage products from Integra Lifesciences (IART), Organogenesis (ORGO), Smith & Nephew (SNN), MiMedx (MDXG), Anika Therapeutics (ANIK) and numerous smaller, private wound care companies. The firm adds that it thinks Integra and Organogenesis both have meaningful exposure to the LCDs based on their product portfolio and the revenue mix within their Advanced Wound Care businesses.